Brigimadlin

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

30 competitors in Solid Tumours

#DrugCompanyPhaseTrials

1

Opdivo

Bristol-Myers Squibb

Phase 2

22

Imfinzi

AstraZeneca

Phase 2

13

Gemzar

Johnson & Johnson

Phase 2

14

Abraxane

Bristol-Myers Squibb

Phase 2

15

Cetrelimab

Johnson & Johnson

Phase 2

16

Hernexeos

Boehringer Ingelheim

Phase 2

17

Adriamycin

Pfizer

Phase 1

18

Imjudo

AstraZeneca

Phase 1

19

AZD0171

AstraZeneca

Phase 2

110

HMBD-001

HHummingbird Bioscience

Phase 2

1Show 7 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Dedifferentiated Liposarcoma2 trials

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Completed·Boehringer Ingelheim·Phase 3·NCT06058793·138 enrolled

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Completed·Boehringer Ingelheim·Phase 2/3·NCT05218499·400 enrolled

Soft Tissue Sarcoma1 trial

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Withdrawn·Boehringer Ingelheim·Phase 3·NCT06370871

Solid Tumours1 trial

A Phase II, Single-arm, Open-label, Long-term Safety Rollover Trial of Oral Brigimadlin in Patients With Solid Tumours

Active, not recruiting·Boehringer Ingelheim·Phase 2·NCT06619509·90 enrolled

Pancreatic Neoplasms1 trial

Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours

Completed·Boehringer Ingelheim·Phase 2·NCT05512377·99 enrolled

Details

Drug Info

Related News